Christine S Zuern1, Konstantinos D Rizas2, Christian Eick1, Marie-Isabel Vogtt1, Boris Bigalke1, Meinrad Gawaz1, Axel Bauer3. 1. Abteilung Innere Medizin III, Department of Cardiology, Eberhard-Karls-Universität Tübingen, Tübingen, Germany. 2. Abteilung Innere Medizin III, Department of Cardiology, Eberhard-Karls-Universität Tübingen, Tübingen, Germany; Munich University Clinic, Ludwig-Maximilians University, Munich, Germany and DZHK (German Centre for Cardiovascular Research). 3. Abteilung Innere Medizin III, Department of Cardiology, Eberhard-Karls-Universität Tübingen, Tübingen, Germany; Munich University Clinic, Ludwig-Maximilians University, Munich, Germany and DZHK (German Centre for Cardiovascular Research). Electronic address: bauer@thebiosignals.org.
Abstract
BACKGROUND: Identification of new risk markers in aortic valve stenosis (AS) is of great interest. Here, we hypothesized that the presence of severe autonomic failure (SAF) is an important prognostic marker in both, symptomatic patients undergoing invasive treatment for severe AS, and in asymptomatic patients with severe AS who were primarily treated conservatively. METHODS: We prospectively enrolled 300 patients with severe AS (aortic valve area<1.0 cm2 or mean aortic gradient>40 mmHg) in sinus rhythm. All patients underwent a 24-h Holter recording for assessment of heart rate turbulence (HRT) and deceleration capacity (DC). Patients with both, abnormal DC and HRT were considered to suffer from SAF. RESULTS: The first hypothesis was tested in 216 symptomatic patients who underwent successful aortic valve replacement (AVR) or transcatheter aortic valve implantation (TAVI). During follow-up of 2 years, 29 of these patients died. SAF was the strongest independent predictor of mortality (hazard ratio 5.6, 95% confidence interval 2.6-12.0; p<0.001) with 2-year mortality rates of 50.0% and 10.7% in SAF-positive and SAF-negative patients, respectively (p<0.001). The second hypothesis was tested in 71 patients, who were asymptomatic at study entry and for whom a primarily conservative treatment strategy was proposed. During follow-up, 10 of these patients died. SAF also predicted death in asymptomatic patients with 2-year mortality rates of 52.4% and 8.7% in SAF-positive and SAF-negative patients, respectively (p=0.010). CONCLUSIONS: SAF is a strong and independent predictor of mortality in symptomatic and asymptomatic patients with severe AS.
BACKGROUND: Identification of new risk markers in aortic valve stenosis (AS) is of great interest. Here, we hypothesized that the presence of severe autonomic failure (SAF) is an important prognostic marker in both, symptomatic patients undergoing invasive treatment for severe AS, and in asymptomatic patients with severe AS who were primarily treated conservatively. METHODS: We prospectively enrolled 300 patients with severe AS (aortic valve area<1.0 cm2 or mean aortic gradient>40 mmHg) in sinus rhythm. All patients underwent a 24-h Holter recording for assessment of heart rate turbulence (HRT) and deceleration capacity (DC). Patients with both, abnormal DC and HRT were considered to suffer from SAF. RESULTS: The first hypothesis was tested in 216 symptomatic patients who underwent successful aortic valve replacement (AVR) or transcatheter aortic valve implantation (TAVI). During follow-up of 2 years, 29 of these patients died. SAF was the strongest independent predictor of mortality (hazard ratio 5.6, 95% confidence interval 2.6-12.0; p<0.001) with 2-year mortality rates of 50.0% and 10.7% in SAF-positive and SAF-negative patients, respectively (p<0.001). The second hypothesis was tested in 71 patients, who were asymptomatic at study entry and for whom a primarily conservative treatment strategy was proposed. During follow-up, 10 of these patients died. SAF also predicted death in asymptomatic patients with 2-year mortality rates of 52.4% and 8.7% in SAF-positive and SAF-negative patients, respectively (p=0.010). CONCLUSIONS:SAF is a strong and independent predictor of mortality in symptomatic and asymptomatic patients with severe AS.
Authors: K Boehm; M Duckheim; L Mizera; P Groga-Bada; N Malek; F Kreth; M Gawaz; C S Zuern; C Eick Journal: Support Care Cancer Date: 2018-04-12 Impact factor: 3.603
Authors: Martin Duckheim; Charlotte Bensch; Linn Kittlitz; Nin Götz; Katharina Klee; Patrick Groga-Bada; Lars Mizera; Meinrad Gawaz; Christine Zuern; Christian Eick Journal: Clin Cardiol Date: 2017-08-28 Impact factor: 2.882
Authors: Casper N Bang; Anders M Greve; Anne B Rossebø; Simon Ray; Kenneth Egstrup; Kurt Boman; Christoph Nienaber; Peter M Okin; Richard B Devereux; Kristian Wachtell Journal: J Am Heart Assoc Date: 2017-11-27 Impact factor: 5.501
Authors: Martin Duckheim; Martin Gaebler; Lars Mizera; Juergen Schreieck; Sven Poli; Ulf Ziemann; Meinrad Gawaz; Christine S Meyer-Zuern; Christian Eick Journal: Medicine (Baltimore) Date: 2021-04-02 Impact factor: 1.817
Authors: José M Torres-Arellano; Juan C Echeverría; Nydia Ávila-Vanzzini; Rashidi Springall; Andrea Toledo; Oscar Infante; Rafael Bojalil; Jorge E Cossío-Aranda; Erika Fajardo; Claudia Lerma Journal: J Clin Med Date: 2021-05-07 Impact factor: 4.241
Authors: Martin Duckheim; Katharina Klee; Nina Götz; Paul Helle; Patrick Groga-Bada; Lars Mizera; Meinrad Gawaz; Christine S Zuern; Christian Eick Journal: Medicine (Baltimore) Date: 2017-12 Impact factor: 1.817